Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 780

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 780
---
15, 2024. Early adoption is permitted. The Company will adopt ASU 2023-07 on January 1, 2024, and it does not expect the adoption to have a material effect on its results of operations, financial position, and cash flows.

3. Available-for-Sale Marketable Securities

As of December 31, 2023 and 2022, the Company’s available-for-sale marketable securities consisted of debt securities issued by the U.S. Treasury, U.S. government-sponsored entities and investment grade institutions (corporate bonds). As of December 31, 2022, the Company’s available-for-sale marketable securities also consisted of debt securities issued by investment grade institutions (commercial paper) and municipal bonds.

The following tables summarize the Company’s available-for-sale marketable securities by major type of security as of December 31, 2023 and 2022:

As of December 31, 2023

| ​                                              
 ​                                              
 Type of Security                               | ​ 
 ​ | ​              
 ​              
 Amortized Cost |      ​ 
      ​ | ​ 
 ​ | ​                
 Gross Unrealized 
 Gains            | ​ | ​ | ​      
 Losses |    ​ | ​ 
 ​ | ​              
 Estimated Fair 
 Value          |      ​ |
|:-----------------------------------------------|:--|:---------------|-------:|:--|:-----------------|--:|:--|:-------|-----:|:--|:---------------|-------:|
| U.S. Treasury securities                       | ​ | $              | 37,243 | ​ | $                | 3 | ​ | $      |    — | ​ | $              | 37,246 |
| U.S. government agency obligations             | ​ |                |  7,500 | ​ |                  | — | ​ |        | -262 | ​ |                |  7,238 |
| Corporate bonds                                | ​ |                |  4,500 | ​ |                  | — | ​ |        |   -1 | ​ |                |  4,499 |
| Total available-for-sale marketable securities | ​ | $              | 49,243 | ​ | $                | 3 | ​ | $      | -263 | ​ | $              | 48,983 |

F-53

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share